Advanced Recomp Stack Protocol - Retatrutide + CJC-1295 (No DAC) + Ipamorelin

Advanced Recomp Stack Quick Reference Card

What Is the Advanced Recomp Stack?

The Advanced Recomp Stack is a three-compound body recomposition protocol combining retatrutide (LY3437943), CJC-1295 without DAC (Modified GRF 1-29), and ipamorelin into a layered approach targeting fat loss, lean mass preservation, and growth hormone optimization simultaneously. The stack pairs the most potent metabolic fat-loss compound currently in clinical development with the most established GH secretagogue combination in the peptide space, creating a two-axis recomposition model: aggressive caloric deficit management via incretin signaling plus endogenous GH elevation to preserve and support lean tissue during that deficit.

This stack addresses a specific limitation of running GLP-1 receptor agonists alone for body recomposition: while retatrutide produces unprecedented fat loss (24-29% body weight reduction in clinical trials), rapid weight loss without GH axis support risks proportional lean mass loss. The CJC-1295 + ipamorelin pairing provides sustained IGF-1 elevation and pulsatile GH release, both associated with improved nitrogen retention, collagen synthesis, recovery, and sleep quality, creating a more favorable environment for lean tissue preservation during aggressive energy deficits.

No direct clinical trial has evaluated the full 3-peptide combination; protocols are extrapolated from individual compound evidence and practitioner/community usage patterns. The rationale is mechanistic: retatrutide operates on incretin and glucagon pathways while CJC-1295 and ipamorelin operate on the GH axis via GHRH and ghrelin receptors respectively, and there is no direct receptor overlap between those systems.

Why Add CJC-1295 + Ipamorelin to Retatrutide?

Retatrutide Foundation

Retatrutide alone delivers the most aggressive pharmacological fat loss documented in clinical trials: 24.2% mean body weight reduction at 48 weeks in Phase 2 and 28.7% at 68 weeks in Phase 3 TRIUMPH-4. It achieves this through triple receptor activation: GLP-1 for appetite suppression and delayed gastric emptying, GIP for insulin sensitivity and lipid metabolism support, and glucagon for hepatic fat oxidation, thermogenesis, and energy expenditure.

Lean Tissue Preservation via Endogenous GH Elevation

The primary limitation of aggressive caloric deficit, whether pharmacological or dietary, is proportional loss of lean mass alongside fat. CJC-1295 (No DAC) stimulates pulsatile GH release via GHRH receptors on pituitary somatotroph cells, while ipamorelin amplifies that signal through the complementary GHS-R1a ghrelin-receptor pathway. Research protocols consistently report higher GH and IGF-1 output from the combination than from either peptide alone, creating an anabolic environment that may counter some of the catabolic pressure retatrutide creates.

Recovery, Sleep Quality, and Training Capacity

GH secretagogues administered before sleep align with the primary overnight window for tissue repair and adaptation. In a recomp context where training stimulus must remain high despite reduced caloric intake, the CJC-1295 + ipamorelin pairing is used to support collagen synthesis, connective tissue recovery, sleep quality, and recovery capacity.

Complementary Fat Mobilization Pathways

Retatrutide drives fat loss mainly through appetite reduction, gastric-emptying modulation, and glucagon-mediated hepatic fat oxidation. GH works through a distinct lipolytic pathway that includes direct stimulation of hormone-sensitive lipase in adipose tissue. The combination therefore targets fat mobilization through both incretin/glucagon signaling and the GH/IGF-1 axis.

No Receptor Overlap - Mechanistic Independence

Retatrutide targets GLP-1R, GIPR, and GCGR; CJC-1295 targets GHRH receptors; and ipamorelin targets GHS-R1a. There is no direct receptor competition or antagonism between the metabolic axis and the GH axis. That mechanistic independence is the core pharmacological basis for combining them.

Advanced Recomp Stack Dosing Protocol & Schedule

Format A: Separate Vials (Standard Protocol)

Protocol Notes

• Injection logistics: Retatrutide is injected once weekly. CJC-1295 and ipamorelin are injected together 1-2x daily. All injections are subcutaneous.
• Fasting requirement for CJC/Ipa: Maintain at least 2 hours fasted before and 30 minutes after injection because insulin blunts GH release.
• 5-on / 2-off scheduling for CJC/Ipa: Community protocols commonly use 5 days on and 2 days off to reduce receptor desensitization potential and manage injection burden.
• Retatrutide GI management: Start at 2 mg regardless of prior GLP-1 experience. Escalate no faster than every 4 weeks. If GI side effects are severe, hold the current dose for an additional 4 weeks before escalating.
• Key warning - do not use CJC-1295 with DAC in this stack. The with-DAC form produces sustained GH elevation rather than pulsatile release and is not the intended fit for this protocol.
• Syringe handling: Use separate insulin syringes for retatrutide versus CJC/Ipa. Label all reconstituted vials clearly because retatrutide is dosed in mg while CJC-1295 and ipamorelin are dosed in mcg.

Advanced Recomp Stack Reconstitution Guide

Format A: Separate Vials

Retatrutide

• Math verification (10 mg vial + 2 mL BAC water): concentration = 10,000 mcg / 2 mL = 5,000 mcg/mL = 5 mg/mL.
• 4 mg dose = 4 mg / 5 mg/mL = 0.8 mL = 80 units on a U-100 syringe.
• 8 mg dose = 8 mg / 5 mg/mL = 1.6 mL = 160 units and requires a larger syringe or split injection.

CJC-1295 (No DAC)

• Math verification (2 mg vial + 1 mL BAC water): concentration = 2,000 mcg / 1 mL = 2,000 mcg/mL.
• 100 mcg dose = 100 / 2,000 = 0.05 mL = 5 units on a U-100 syringe.
• 200 mcg dose = 200 / 2,000 = 0.10 mL = 10 units.

Ipamorelin

• Math verification (5 mg vial + 2.5 mL BAC water): concentration = 5,000 mcg / 2.5 mL = 2,000 mcg/mL.
• 200 mcg dose = 200 / 2,000 = 0.10 mL = 10 units.

CJC-1295 and ipamorelin are also commonly available as pre-blended vials such as 5 mg CJC-1295 / 5 mg ipamorelin. For a blend vial reconstituted with 2 mL BAC water, total concentration is 5,000 mcg/mL with 2,500 mcg/mL per peptide. Drawing 0.08 mL (8 U) delivers approximately 200 mcg of each peptide per injection.

Standard 7-Step Reconstitution (Per Vial)

1. Gather supplies: sterile U-100 insulin syringe (29-31 gauge), bacteriostatic water, alcohol swabs, and the peptide vial.
2. Wipe the rubber stopper of both the BAC water vial and the peptide vial with alcohol swabs and allow to air dry.
3. Draw the calculated volume of BAC water into the syringe using the target concentration from the tables above.
4. Insert the needle into the peptide vial and inject BAC water slowly down the inner glass wall; do not spray directly onto the lyophilized powder.
5. Allow the vial to sit for 1-2 minutes. Do not shake. Gently roll between the palms or swirl until fully dissolved.
6. Label the vial with compound name, concentration, and reconstitution date.
7. Store the reconstituted vial in the refrigerator at 2-8 C immediately. Never freeze reconstituted peptides.

Repeat the reconstitution steps for each compound vial in the stack: three separate reconstitutions for three separate vials, or two total if using a CJC/Ipa blend vial plus one retatrutide vial.

Advanced Recomp Stack Side Effects & Safety

Individual compounds have established safety profiles from clinical trials (retatrutide) and pharmacological studies (CJC-1295 and ipamorelin), but no trial has tested the 3-compound combination. The following represents the combined risk profile based on individual compound data and mechanistic considerations.

Retatrutide-Specific Side Effects (Phase 3 TRIUMPH-4 Data, December 2025)

• Nausea: 38-43% (dose-dependent; primarily during escalation).
• Diarrhea: 33-35%.
• Constipation: 22-25%.
• Vomiting: 20-21%.
• Decreased appetite: 18-19%.
• Dysesthesia: 8.8% at 9 mg and 20.9% at 12 mg, a retatrutide-specific signal tied to glucagon receptor activity.
• Heart rate increase: roughly 5-10 bpm above baseline, peaking around week 24 and declining thereafter.
• Discontinuation due to adverse events: 12-18%.

CJC-1295 (No DAC) + Ipamorelin Side Effects

• Injection-site reactions such as redness or mild swelling.
• Transient flushing or warmth post-injection.
• Water retention or mild edema.
• Headache, usually resolving within the first 2 weeks.
• Mild hunger increase from ipamorelin's ghrelin mimicry.
• Transient fatigue or lightheadedness.
• Tingling or numbness in the extremities at higher GH-related exposure.

Combined or Amplified Concerns

• GI burden management: Retatrutide already carries significant GI side effects during escalation. Adding daily CJC/Ipa injections increases injection burden but does not directly amplify GI motility effects.
• Water retention: Both retatrutide and CJC/Ipa can independently contribute to mild fluid retention, which may be more noticeable in the first 4-6 weeks.
• Heart rate monitoring: Retatrutide independently raises heart rate. Individuals with pre-existing cardiovascular concerns should monitor more carefully.
• Glucose metabolism: Retatrutide improves glycemic control while GH has a counter-regulatory effect on insulin sensitivity. Those with pre-diabetes or insulin resistance should monitor glucose response.
• Multi-source contamination risk: Running three separate research peptides from grey-market sources multiplies quality-control risk. The guide specifically recommends COA-verified suppliers.

Clinical Evidence Context

Stack evidence model: retatrutide drives the energy deficit and metabolic fat loss with direct human Phase 2 and Phase 3 evidence, while CJC-1295 + ipamorelin provides endogenous GH and IGF-1 elevation to support lean tissue preservation during that deficit, supported mainly by human pharmacokinetic data and community practice rather than stack-level outcome trials.

Storage & Handling

Limiting factor: ipamorelin reconstituted stability at 3-4 weeks is the shortest window. Plan reconstitution cycles around ipamorelin stability and consider fresh vials every 3 weeks for optimal potency.

Do not freeze any reconstituted peptide. Freezing can damage peptide structure and reduce potency. Unreconstituted lyophilized powder can be stored frozen for longer-term storage.

Advanced Recomp Stack vs CagriSema vs Retatrutide Solo

Decision Guidance

• Choose the Advanced Recomp Stack when body recomposition, not just fat loss, is the primary goal and you are comfortable with a more complex daily-plus-weekly injection protocol.
• Choose CagriSema when convenience is the priority and the goal is strong weight loss with a single weekly injection.
• Choose Retatrutide Solo when maximum fat loss is the primary goal and lean-mass protection will be handled through diet and resistance training rather than GH-secretagogue support.

Related Stacking Protocols

CagriSema Stack (Cagrilintide + Semaglutide)

Dual incretin/amylin weight-loss stack and the closest evidence-backed single-injection recomp alternative. CagriSema Stack Protocol

Cagrilintide + Retatrutide Stack

Combines amylin-based satiety with triple-agonist metabolic fat loss for a deeper energy-balance intervention. Cagrilintide + Retatrutide Stack Protocol

Wolverine Stack (BPC-157 + TB-500)

If tissue repair and injury recovery are priorities alongside body recomposition, the Wolverine Stack is the most relevant complementary repair-oriented protocol. Wolverine Stack Protocol

Russian Nootropic Stack (Semax + Selank)

Useful when cognitive fog or mood disruption becomes a constraint during aggressive caloric deficit. Russian Nootropic Stack Protocol

Frequently Asked Questions - Advanced Recomp Stack

Sources & Research

1. Jastreboff AM, Kaplan LM, Frias JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." New England Journal of Medicine, 2023 Link.
2. Eli Lilly and Company. "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press Release, 2025 Link.
3. Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
4. Ionescu M, Bhatt DL, Giles K, et al. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
5. Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 1998 Link.
6. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical Research, 1999 Link.
7. Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial." The Lancet, 2023 Link.
8. Hartman ML, Veldhuis JD, Johnson ML, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2a Trial." Nature Medicine, 2024 Link.
9. Ishida J, Saitoh M, Ebner N, et al. "Growth hormone secretagogues: history, mechanism of action, and clinical development." JCSM Rapid Communications, 2020 Link.
10. Alba M, Fintini D, Sagazio A, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology - Endocrinology and Metabolism, 2006 Link.
11. ClinicalTrials.gov. "A Study of Retatrutide (LY3437943) Once Weekly in Participants With Obesity and Knee Osteoarthritis (TRIUMPH-4)." Identifier: NCT05931367. Clinical Trial Registry, n.d. Link.
12. Urva S, Coskun T, Loh MT, et al. "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial." The Lancet, 2022 Link.

Related Protocols

Disclaimer